Effects of Almonds on Insulin Sensitivity in Prediabetes

Completed · Not applicable

Conditions studied: PreDiabetes

In brief

The goal of this clinical trial is to evaluate the effects of consuming 1.5 oz almonds twice daily on insulin sensitivity and markers of cardiometabolic health in men and women with prediabetes.

Key facts

Study ID

NCT03126981

Run by

Midwest Center for Metabolic and Cardiovascular Research

People needed

54

Starts

2017-04-20

Expected to finish

2018-09-26

Last updated by the study team

2019-07-24

Who can join

Age: 18 and older, up to 69. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• BMI of 25.0-39.9 kg/m2
• Prediabetic: fingerstick glycated hemoglobin 5.7-6.4% (inclusive), or fasting fingerstick capillary glucose of 100-125 mg/dL (inclusive), or 2-h post-prandial glucose of 140-199 mg/dL.
• Fasting LDL-C level <200 mg/dL and fasting TG level <400 mg/dL.
• Judged to be in general good health on the basis of medical history and screening laboratory tests.

You may not qualify if…

• Atherosclerotic cardiovascular disease including any of the following: clinical signs of atherosclerosis: peripheral arterial disease, abdominal aortic aneurysm, carotid artery disease [symptomatic (e.g., transient ischemic attack or stroke of carotid origin) or >50% stenosis on angiography or ultrasound], history of myocardial infarction, angina, a revascularization procedure, or other forms of clinical atherosclerotic disease (e.g., renal artery disease).
• History or presence of clinically important pulmonary (including uncontrolled asthma), endocrine (including type I or type II diabetes mellitus), chronic inflammatory disease (including irritable bowel disease, lupus, rheumatoid arthritis), hepatic, renal, hematologic, immunologic, dermatologic, neurologic, psychiatric, or biliary disorders.
• Known allergy, sensitivity, or intolerance to any ingredients in the study foods.
• Uncontrolled hypertension.
• Recent history of cancer, except for non-melanoma skin cancer.
• Recent change in body weight of ± 4.5 kg (9.9 lbs).
• Recent use of any medications intended to alter the lipid profile (e.g. bile acid sequestrants, cholesterol absorption inhibitor, fibrates, niacin (drug form), omega-3-ethyl ester drugs, and/or PCSK9 inhibitors, with the exception of the stable use of statins), weight-loss drugs or programs, systemic corticosteroid drugs, unstable use of any antihypertensive medication; medications known to influence CHO metabolism (e.g. adrenergic receptor blockers, diuretics, and/or hypoglycemic medications).
• Recent use of food/supplements known to influence lipid metabolism (e.g. omega-3 fatty acid supplements (e.g., flaxseed, fish or algal oils) or fortified foods, sterol/stanol products; dietary supplements (red rice yeast supplements; garlic supplements; soy isoflavone supplements; niacin or its analogues at doses >400 mg/d, and irregular or inconsistent use of Metamucil® or viscous fiber-containing supplements.
• Recent use of antibiotics.
• Pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period.
• Extreme dietary habits (e.g. very low CHO diet, vegan, etc.).
• Current or recent history, or strong potential, for drug or alcohol abuse.
• History of a diagnosed eating disorder. -

Where it is running

• MB Clinical Research — Boca Raton, Florida, United States
• Illinois Institute for Food Safety and Health (IFSH) at Illinois Instiute of Technology (IIT) — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.